(Q33750445)

29 July 2017

1 reference

title

5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy (English)

1 reference

29 July 2017

1 reference

1 reference

1 reference

2

Ratain MJ

1 reference

29 July 2017

Iyer L

1

1 reference

29 July 2017

1 January 1999

1 reference

29 July 2017

1 reference

29 July 2017

17

1 reference

29 July 2017

7

1 reference

29 July 2017

494-506

1 reference

Preclinical and clinical aspects of biomodulation of 5-fluorouracil

29 July 2017

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

The role of interferon-α as a modulator of fluorouracil and leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Clinical pharmacology of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Biochemical Basis for Circadian-Dependent Metabolism of Fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

cDNA cloning of bovine liver dihydropyrimidine dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Mutations at codon 974 of the DPYD gene are a rare event

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Incorporation of 5-substituted uracil derivatives into nucleic acids. Part IV. The synthesis of 5-ethynyluracil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Report on nationwide pooled data and cohort investigation in UFT phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Oral chemotherapy: rationale and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

5-Fluorouracil by protracted venous infusion. A review of current progress

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909909032859

10.3109/07357909909032859

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10518194